INS and type 1 diabetes mellitus: In a pioneering study by Herold et al. in 2019, 24 participants newly diagnosed with T1DM were randomly assigned to receive either teplizumab or placebo.31 Treatment within 6 weeks of diagnosis with a single course of antibodies led to maintained or improved insulin production after 1 year (p=0.01).